drugset / Trial / NCT03405142
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2019-12-04
- Completion
- 2021-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 50 mg | Intravenous |
| Subject | Technetium Tc 99m Tilmanocept | Diagnostic / imaging agent | 74 mbq | Other |